BCY LifeSciences, Inc.
Pharma firm records decrease in research, development expenses
Published in Lab Business Week, July 3rd, 2005
In the 3-month period ended March 31, 2005, the company incurred research and development expenses of $3,105, a decrease of $125,265 from the $128,370 incurred in the 3-month period March 31, 2004. Expenses in the first quarter were lower than in the previous quarter as the company completed its phase II clinical trial and reports relating to the scientific development of DCF 987 in 2004.
These expenditures are expected to remain at a minimum level as future development of DCF 987 will be undertaken by Align Pharmaceuticals, Inc., (ALIGN). Government assistance...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2005-07-03)
More Articles from Lab Business Week
- Abiomed, Inc.
Device firm reports loss of $0.11 per share - Advanced Magnetics, Inc.
Pharmaceutical firm closes $13.8M stock sale - Aerogen, Inc.
Pharmaceutical company gets Nasdaq listing determination - Allon Therapeutics, Inc.
Neuroscience company reports clinical pipeline update, loss of $0.04 per share - Amarin Corporation plc
Neuroscience company reports loss of $0.09 per share - Biovail Corporation
Pharmaceutical firm renews revolving term credit facility - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
